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Abstract
Background: Over-expression of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in
tumor tissue is associated with insensitivity to 5-fluorouracil (5-FU). Over-expression of ERCC1 correlates with
insensitivity to oxaliplatin (OX) therapy, while high thymidine phosphorylase (TP) levels predict for increased
sensitivity to capecitabine (Xel).
Methods: Biopsies of metastatic tumor were taken before OX (130 mg/m2 day 1) given with Xel (1200–3000
mg/m2 in two divided doses days 1–5 and 8–12) every 3-weeks. Micro-dissected metastatic and primary tumors
were analyzed for relative gene expression by real-time quantitative polymerase chain reaction. The clinical
protocol prospectively identified the molecular targets of interest that would be tested. Endpoints for the
molecular analyses were correlation of median, first and third quartiles for relative gene expression of each target
with response, time to treatment failure (TTF), and survival.
Results: Among 91 patients participating in this trial; 97% had colorectal cancer. The median number of prior
chemotherapy regimens was 2, and most had prior 5-FU and irinotecan. In paired samples, median mRNA levels
were significantly higher in metastatic versus primary tumor (-fold): TS (1.9), DPD (3.8), ERCC1 (2.1) and TP (1.6).
A strong positive correlation was noted between DPD and TP mRNA levels in both primary (r = 0.693, p <
0.0005) and metastatic tissue (r = 0.697, p < 0.00001). There was an association between TS gene expression and
responsive and stable disease: patients whose intratumoral TS mRNA levels were above the median value had
significantly greater risk of early disease progression (43% vs 17%), but this did not translate into a significant
difference in TTF. ERCC1 gene expression above the third quartile was associated with a shorter TTF (median
85 vs 162 days, p = 0.046). Patients whose TS mRNA levels in metastatic tumor tissue were below the median
had a longer overall survival (median 417 vs 294 days, p = 0.042).
Conclusion: Target gene expression in primary tumor was significantly lower than that in paired metastatic
tissue. High ERCC1 mRNA levels in metastatic tumor was associated with a shorter TTF. Lower expression of
TS mRNA correlated with a lower chance of early PD with XelOX therapy and improved overall survival.
Published: 23 December 2008
BMC Cancer 2008, 8:386 doi:10.1186/1471-2407-8-386
Received: 27 January 2008
Accepted: 23 December 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/386
© 2008 Uchida et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:386 http://www.biomedcentral.com/1471-2407/8/386
Page 2 of 10
(page number not for citation purposes)
Background
It is estimated that about 153,000 new cases of colorectal
cancer will be diagnosed in the U.S. in 2007 [1]. 5-fluor-
ouracil (5-FU), floxuridine (FUDR), capecitabine (Xel),
irinotecan, oxaliplatin (OX), cetuximab, panitumumab
and bevacizumab are licensed in the U.S. for use in
patients with colorectal cancer. Although each of these
agents has clinical activity in patients with colorectal can-
cer, primary and acquired treatment resistance is com-
mon. Identification of molecular markers at either the
intra-genic, chromosomal, mRNA or protein level that
might predict whether colorectal cancer patients are likely
to benefit from systemic therapy is a subject of intense
investigation.
Prognostic markers provide information about the proba-
ble course of the disease in individual patients and the
chances of remaining progression- or disease-free or sur-
viving independent of the therapy received. Predictive
markers reflect the chance of benefit from a specific thera-
peutic intervention. A variety of retrospective studies have
been performed over the past decade to identify molecu-
lar markers that may correlate with metastatic colorectal
cancer response to 5-FU-based therapy. Expression of
individual genes at the mRNA level can be determined
using real-time reverse transcription, polymerase chain
reaction (RT-PCR). Immunohistochemistry (IHC),
enzyme-linked immunosorbent assays, and measurement
of enzymatic activity may be employed to assess protein
content. Analysis of genetic polymorphisms is a more
recent approach.
Many of these retrospective studies in advanced colorectal
cancer used various schedules of 5-FU modulated by leu-
covorin. With the availability of new agents with different
mechanisms of action, and second- and third-line salvage
therapies, the question of whether a given molecular
marker will retain prognostic and/or predictive value is a
subject of ongoing investigation.
5-FU exerts cytotoxicity by both RNA- and DNA-directed
mechanisms. With the use of leucovorin and continuous
infusion schedules, the contribution of thymidylate syn-
thase (TS) inhibition is thought to be of primary impor-
tance. Inhibition of TS by 5-fluoro-2'-deoxyuridine
monophosphate leads to imbalance of deoxyribonucle-
otide triphosphate pools (depletion of thymidine triphos-
phate, accumulation of deoxyuridine triphosphate and
deoxyadenosine triphosphate), interference with DNA
synthesis and repair, and induction of DNA strand breaks
[2]. A variety of pre-clinical studies have demonstrated
that over-expression of TS is associated with insensitivity
to 5-FU. Several clinical studies that analyzed TS protein
or mRNA expression in metastatic tumor tissue support
the observation that low TS expression predicts for
response [3-11].
Thymidine phosphorylase (TP) catalyzes the reversible
conversion of thymidine to thymine and 5-fluoro-2'-
deoxyuridine to 5-FU, a process that is influenced by the
availability of 2'-deoxyribose-1-phosphate [12]. TP, also
known as platelet-derived endothelial growth factor,
appears to play a role in angiogenesis. High intratumoral
TP expression has been associated with insensitivity to 5-
FU therapy in some pre-clinical and clinical studies [13-
15]. Capecitabine is an oral 5-FU pro-drug that is con-
verted to 5-FU through a series of three enzymatic steps;
intracellular TP mediates the final conversion of 5'-doxy-
5-fluorouridine (doxifluridine) to 5-FU. Over-expression
of TP in preclinical models is associated with increased
sensitivity to capecitabine or doxifluridine, due to greater
conversion to 5-FU [16,17]. TP is over-expressed in many
human tumors compared to adjacent normal tissue, pro-
viding a potential for selective formation of 5-FU in tumor
tissue [18]. Several studies have reported a correlation
between elevated TP (as measured by either IHC or ELISA)
and benefit with doxifluridine therapy [19-21].
Dihydropyrimidine dehydrogenase (DPD) catalyzes the
rate-limiting step in the catabolism of 5-FU. Several clini-
cal studies suggest that over-expression of DPD in colorec-
tal tumor tissue is associated with poor response to 5-FU-
based therapy [15,22-24].
Mammalian excision repair cross complementing protein
(ERCC1) is involved in the repair of damaged DNA [25-
27], and acts in concert with xeroderma pigmentosum
protein F (XPF, also known as ERCC4 protein), which sta-
bilizes ERCC1. This polypeptide complex introduces an
incision on the 5' side of a damaged site in DNA. The
ERCC1/XPF endonuclease complex is implicated in the
repair of two distinct types of lesions in DNA: nucleotide
excision-repair (NER), which is involved in repair of ultra-
violet-induced lesions and bulky chemical adducts, and
recombination repair of inter-strand cross-links. Over-
expression of ERCC1 has been reported in cisplatin-resist-
ant cancer cell lines [27]. Clinical data suggests that high
intratumoral levels of ERCC1 mRNA are associated with
insensitivity to oxaliplatin-based therapy in colorectal
cancer [10].
The main purpose of this study was to determine a recom-
mended dose of Xel given in combination with a fixed
dose of OX on an every 3-week schedule. Correlations
between gene expression of four molecular targets in
tumor tissue and clinical outcome was a secondary end-
point.
Methods
Subjects were participating in a Phase I study examining
the feasibility of administering a fixed dose of oxaliplatin
with escalating doses of capecitabine to patients with
advanced colorectal or small bowel adenocarcinoma. TheBMC Cancer 2008, 8:386 http://www.biomedcentral.com/1471-2407/8/386
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protocol was approved by the Cancer Therapy Evaluation
Program, NCI, and Institutional Review Boards of the NCI
and the National Naval Medical Center. All patients gave
written informed consent.
Oxaliplatin 130 mg/m2 was infused by vein over 2-hours
on day one, while a total daily dose of capecitabine rang-
ing from 1,200 to 3,000 mg/m2 was given in two divided
doses on days 1–5 and 8–12 of a planned 21-day cycle.
Therapy was continued until evidence of disease progres-
sion occurred, unacceptable toxicity developed, or the
patient elected to withdraw. Assessment of disease status
was planned every three cycles.
Biopsies of metastatic tumor were obtained in 81 patients.
Samples were placed in RNALater® (Ambion Inc., Austin,
TX, USA), stored at 4°C overnight, then stored at -30°C.
Archival primary tumor tissue was available as formalin
fixed, paraffin embedded (PFFE) tissue blocks in 27% of
patients.
The clinical protocol document prospectively identified
the four molecular targets of interest that would be tested,
and specified that the median, first and third quartile val-
ues for relative gene expression for each of the four genes
for all informative samples would be correlated with clin-
ical outcome to see if there were any associations with
greater or lesser mRNA expression.
Micro-dissection
The frozen samples that had been stored in RNALater®
were embedded in optimal cutting temperature (OCT)
compound (Secure Fanatic U.S.A., Inc., Torrance, CA) and
cut into serial sections with a thickness of 20 am. Sections
were mounted on unbolted glass slides and stored at -
80°C. For histology diagnosis, three representative sec-
tions, consisting of the beginning, middle and end of sec-
tioning were stained with hematoxylon and eosin (H&E)
by the standard method.
Before micro-dissection, sections were air-dried, fixed in
70% ethanol for 3 min and washed in water for 2 min.
Afterwards, they were stained with nuclear fast red (NER,
American MasterTech Scientific, Inc., Lodi, CA, USA) for
10 sec and again washed in water for 30 sec. Samples were
then dehydrated in a stepwise manner with 70% ethanol,
95% ethanol and 100% ethanol for 30 sec each, followed
by incubation in xylene for 5 min and complete air-dry-
ing. All H&E stained sections were evaluated by a pathol-
ogist. If the histology of the samples was homogeneous
and contained more than 90% tumor tissue, samples were
dissected from the slides using a scalpel. All other sections
were selectively isolated by LCM (P.A.L.M. Microsystem,
Leica, Wetzlar, Germany) according to the standard proce-
dure [28]. The micro-dissected tissue was transferred to a
reaction tube containing 400 μL of RNA lysis buffer.
RNA extraction
For extraction from FFPE specimens, the tissue samples to
be extracted were placed in a 0.5 mL, thin walled tube con-
taining 400 μL of 4 M dithiothreitol (DTT)-GITC/sarc (4
M guanidinium isothiocyanate, 50 mM Tris-HCl, pH 7.5,
25 mM EDTA) (Invitrogen; #15577-018). The samples
were heated at 92°C for 30 min and then transferred to a
2 mL centrifuge tube. To the tissue suspensions were
added 50 μL of 2 M sodium acetate, pH 4.0, followed by
600 μL of freshly prepared phenol/chloroform/isoamyl
alcohol (250:50:1). The tubes were vortex-mixed for 15
sec, placed on ice for 15 min and then centrifuged at
13,000 rpm for 8 min in a chilled (8°C) centrifuge. The
upper aqueous phase (250–350 μL) was carefully
removed and placed in a 1.5 mL centrifuge tube. Glycogen
(10 μL) and 300–400 μL of isopropanol were added and
the samples vortex-mixed for 10–15 sec. The tubes were
placed at -20°C for 30–45 min to precipitate the RNA. The
samples were then centrifuged at 13,000 rpm for 7 min in
a chilled (8°C) centrifuge. The supernatant was poured
off and 500 μL of 75% ethanol was added. The tubes were
centrifuged at 13,000 rpm for 6 min in a chilled (8°C)
centrifuge. The supernatant was carefully poured off so as
not to disturb the RNA pellet and the samples were quick-
spun for 15 sec at 13,000 rpm. The remaining ethanol was
removed with a 20 μL pipette and the samples air-dried
for 15 min. The pellet was re-suspended in 50 μL of 5 mM
Tris. For RNA extraction from OCT embedded samples,
the above procedure was followed, except that the step
involving heating at 92°C for 30 min was omitted.
cDNA Preparation and Real Time PCR Quantification of 
mRNA Expression
cDNA was prepared as previously described [29]. Quanti-
tation of TS, TP, ERCC1 and DPD and an internal refer-
ence gene (β-actin) was done using a fluorescence based
real-time detection method (ABI PRISM 7900 Sequence
detection System, Perkin-Elmer (PE) Applied Biosystem,
Foster City, CA, USA). The PCR reaction mixture consisted
1200 nM of each primer, 200 nM probe, 0.4 U of Ampli-
Taq Gold Polymerase, 200 nM each dATP, dCTP, dGTP,
dTTP, 3.5 mM MgCl2 and 1× Taqman® Buffer A containing
a reference dye, to a final volume of 20 μl (all reagents
from PE Applied Biosystems, Foster City, CA, USA).
Cycling conditions were 50°C for 2 min, 95°C for 10
min, followed by 46 cycles at 95°C for 15 sec and 60°C
for 1 min. The primers and probes used are shown in
Table 1.
The cycle after which the fluorescent signal exceeds the
threshold is referred to as the Ct. The Ct is inversely pro-BMC Cancer 2008, 8:386 http://www.biomedcentral.com/1471-2407/8/386
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portional to the amount of cDNA in the tube, i.e., a higher
Ct value means that more PCR cycles are required to reach
a certain level of detection. Gene expression values (rela-
tive mRNA levels) are expressed as ratios (differences
between the Ct values) between the genes of interest and
an internal reference gene (β-actin) that provides a nor-
malization factor for the amount of RNA isolated from a
specimen. Each cDNA sample had a duplicate genomic
sample analyzed by real-time PCR without reverse tran-
scription. If a fluorescent signal above the threshold was
seen in the no reverse transcription specimen, the results
from the corresponding cDNA were not deemed reliable.
Each plate contained a reference cDNA sample to allow
normalization for potential plate to plate variability.
Validation of the assay was performed with regard to RNA
extraction and recovery, accuracy, precision, limits of
quantitation and range. These studies followed GLP
guidelines and employed Stratagene reference human
RNA mix, pooled tissue homogenates derived from FFPE
tissue sections and multiple sections of FFPE tumor sec-
tions from a variety of tumors. Assay precision was
inferred from the variation in the replicate Ct values for all
genes used, and had no more than 5.3% coefficient of var-
iation (CV). The Delta Ct values derived from these Ct val-
ues showed a maximum %CV of 9.5%. This was expected,
since the Delta Ct values reflect the variation in the Ct val-
ues of two genes, the target gene and its actin reference
gene.
Statistical and Graphical Analysis
Statistical analyses were performed using SigmaStat for
Windows Version 3.11 (Systat Software Inc., Richmond,
CA, USA). The median, first and third quartile values for
each molecular marker were determined using all inform-
ative samples. The distribution of response vs. stable dis-
ease vs. early progressive disease as a function of
molecular marker expression was analyzed by the chi-
square test, whereas differences in response plus stable
disease vs. early progressive disease was by Fisher's exact
test. The strength of association of two variables was deter-
mined by the Pearson product moment correlation. Anal-
ysis of progression-free survival was performed by log-
rank. Overall survival was analyzed by the Gehan-Breslow
method. Graphs were prepared using SigmaPlot for Win-
dows version 9.0 (Systat Software, Inc., Chicago, IL).
Results
Patient Characteristics and Clinical Outcome
Ninety-one subjects participated in this clinical trial
(Table 2). One patient withdrew after having a tumor
biopsy performed, and did not receive any protocol ther-
apy. Six additional patients are not assessable for
response. Among 84 subjects who were considered assess-
able for response to protocol therapy, there were four
complete and 14 partial responses (21%). Forty-five
patients had stable disease (54%), while 21 (25%) experi-
enced clinical or radiographic evidence of disease progres-
sion by the time of initial restaging after 3 cycles. For all
Table 1: Sequences of primers and probes
Target Forward Primer Reverse Primer
TS GCCTCGGTGTGCCCTTTCA CCCGTTGATGTGCGCAAT
TP CCTGCGGACGGAATCCT TCCACGAGTTTCTTACTGAGAATGG
DPD AGGACGCAAGGAGGGTTTG GTCCGCCGAGTCCTTACTGA
ERCC1 GGGAATTTGGCGACGTAATTC GCGGAGGCTGAGGAACGA
β-actin TGAGCGGGCTACAGCTT TCCTTAATGTCACGCACGATTT
Target Probe: 6-FAM-5', 3'-TAMRA
TS TCGCCAGCTACGCCCTGCTCA
TP CAGCCAGAGATGTGACAGCCACCG
DPD CAGTGCCTACAGTCTCGAGTCTGCCAGTG
ERCC1 CACAGGTGCTCTGGCCCAGCACATA
β-actin ACCACCACGGCCGAGCGGBMC Cancer 2008, 8:386 http://www.biomedcentral.com/1471-2407/8/386
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91 subjects, the median time to treatment failure was 5.1
months, and the median survival was 10.9 months.
Tumor Tissue
Biopsies of metastatic tumor tissue were obtained in 81
subjects. Fifteen of these samples were not informative for
any of the four targets of interest, either due to absence of
tumor in the sample, or an insufficient quantity of tissue.
The number of samples that were informative for each tar-
get was as follows: TS, 65; DPD, 63; TP, 64; ERCC1, 64.
Archival paraffin-embedded formalin fixed tissue blocks
from the primary tumor were available in 25 subjects. No
tumor was seen in one of these. One additional subject
had a biopsy of a rectal primary that was stored in
RNALater®. The median time from initial diagnosis to
study entry in subjects who had both archival primary
tumor tissue and metastatic tumor tissue was 671 days
(25th%, 426; 75th%, 824).
Table 3 shows the results of the gene expression for the
pre-selected molecular targets. There was much greater
variability in the distribution of values for each molecular
target in metastatic tissue: the ratio of the maximum to
minimum values ranged from 24 to 95. In primary tumor
tissue, in contrast, the ratio of maximum to minimum val-
ues for each target ranged from 9 to 14.
When mRNA expression was compared in paired samples
of primary and metastatic tumor tissue, gene expression
was significantly higher in metastatic tumor tissue for
each molecular marker: TS, 1.9-fold; DPD, 3.8-fold; TP,
1.6-fold; ERCC1, 2.1-fold (Figure 1).
The strength of association between doublets of molecu-
lar markers was analyzed. In both primary and metastatic
tumor tissue, there was a strong correlation between the
expression of DPD and TP (Figure 2). No other significant
correlations were observed.
Restaging computerized tomographic scans were planned
after the first three cycles (nine weeks). Individual target
gene expressions were stratified as above or below either
the median, first or third quartile. The proportion of
observations in the different categories that defined the
contingency tables were analyzed by comparing complete
and partial response (CR and PR) versus stable disease
(SD) versus early progressive disease (PD, within the first
9 weeks), or CR plus PR plus SD versus early PD. The only
association that appeared to be non-random was with TS
(Table 4). Patients whose intra-tumor TS mRNA levels
were above the median value had significantly greater risk
of early disease progression (43% vs 17%). Subjects who
Table 2: Patient demographics (n = 91)
Median Age (Range) 56 yr (26–74)
Performance Status (ECOG)
04 5
14 0
26
Male/Female 61/30
Primary Tumor Site
colon 69
rectum 19
appendix 2
jejunum 1
Number Prior Chemotherapy Regimens
04
14 0
23 7
31 0
Prior 5-fluoropyrimidine 87
Prior Irinotecan 73
Prior Radiation 19
Table 3: Relative gene expression in tumor tissue (vs. β-actin)
Molecular Marker TS DPD TP ERCC1
M e t a s t a s i s  ( N o . ) 6 56 36 4 6 4
Median (range) 3.91 (0.81–77.58) 1.62 (0.15–11.89) 5.64 (1.06–31.89) 2.17 (0.34–8.23)
25th%, 75th% 2.38, 6.31 0.92, 3.04 3.77, 10.34 1.48, 3.36
Primary (No.) 24 21 24 25
Median (range) 2.07 (0.5–4.49) 0.36 (0.15–1.41) 3.23 (0.71–10.02) 1.04 (0.34–3.28)
25th%, 75th% 1.26, 2.58 0.21, 0.55 1.54, 4.98 0.64, 1.55BMC Cancer 2008, 8:386 http://www.biomedcentral.com/1471-2407/8/386
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had very high intra-tumor ERCC1 expression tended to
have an increased risk of early PD (47% vs 22%).
Because a major endpoint of this study was tolerability of
the regimen, a primary endpoint was time to treatment
failure, which was defined as the interval from enrollment
on study to either documented disease progression or the
date a patient withdrew from the study for unacceptable
toxicity. Only two patients withdrew from study due to
unacceptable toxicity accompanied by a decline in per-
formance status. Neither patient had a restaging CT scan,
so the date of progression cannot be determined. When
individual molecular marker expression was analyzed as a
possible predictive factor for TTF, those subjects whose
metastatic tumor tissue had ERCC1 gene expression above
the third quartile had a significantly shorter TTF of 77 days
(Figure 3). If the two patients who withdrew for toxicity
are excluded, the result did not appreciably change: those
with ERCC1 gene expression above the third quartile was
significantly shorter: median TTF 85 days vs 166 days (p =
0.017). Various combinations of molecular markers did
not discriminate any apparent differences in TTF.
Overall survival from the on-study date was analyzed
according to higher versus lower mRNA expression of
individual targets. The only individual molecular marker
that tended to distinguish those with worse or better sur-
vival was TS (Figure 4). The median survival in subjects
whose metastatic tumor tissue had TS mRNA expression
below the median was 123 days longer than those with TS
expression above the median. Various combinations of
molecular marker expression were analyzed (e.g. TS below
median and ERCC1 below third quartile vs others), but
none yielded stronger prognostic information than TS
mRNA expression alone.
Discussion
The objective response rate was 21% in this heterogenous
patient population with a median of two prior chemo-
therapy regimens. mRNA expression of TS, DPD, ERCC1
Gene expression in paired primary and metastatic tumor tissue samples Figure 1
Gene expression in paired primary and metastatic tumor tissue samples. The data are shown in box-plot format; all 
outliers are shown. The p values are from a Wilcoxon signed rank test.
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and ERCC1 in paired metastatic and primary tumor was
significantly higher in metastatic tissue. This may in part
be explained by the long interval from initial diagnosis to
study entry (median 671 days). It is acknowledged that
mRNA from primary tissue was derived from formalin
fixed paraffin-embedded samples while metastatic tissues
were immediately placed in RNA later and frozen. Frozen
tissues typically generate more RT-PCR product than FFPE
tissues [30]. However, normalization of gene expression
to β-actin gene expression in the same tissue should cor-
rect for any relative differences in efficiency of RT-PCR
product.
In both metastatic and primary tissue, there was a signifi-
cant correlation between DPD and TP mRNA expression.
The genes encoding DPD and TP are located on chromo-
somes 1p22 and 22q13, respectively. Other investigators
have also reported a significant correlation between
mRNA levels of DPD and TP in both primary and meta-
static tumor tissue [31,32]. Further studies would be
needed to see if these genes are coordinately regulated.
Due to the small sample size and heterogeneity of the
patient population, the results and conclusions of this
analysis must be interpreted with caution. It appeared that
TS mRNA expression below or above the median tended
to distinguish those subjects who achieved either objec-
tive response or stable disease vs. those who had early dis-
ease progression within 9 weeks of enrolling on protocol.
Subjects whose metastatic tumor tissue had ERCC1
Correlation between DPD and TP gene expression in either  primary or metastatic tumor tissue Figure 2
Correlation between DPD and TP gene expression in 
either primary or metastatic tumor tissue. The Pear-
son product moment correlation coefficient and p-value are 
shown.
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Table 4: Gene expression and disease control with XelOX 
therapy
CR+PR+SD PD total
TS ≤ median 25 5 30
TS > median 17 13 30
ERCC1 ≤ 75th%3 5 1 0 4 5
ERCC1 > 75th%8 7 1 5
Six subjects were not assessable for response; therefore, only 60 
subjects each with informative TS and ERCC1 samples from 
metastatic tumor tissue are included in the analysis between gene 
expression and disease control. The Fisher exact test p-value was 
0.047 for TS and 0.099 for ERCC1.
Time to treatment failure as a function of ERCC1 gene  expression Figure 3
Time to treatment failure as a function of ERCC1 
gene expression. The median TTF was 162 days in those 
with ERCC1 expression < 3rd quartile (n = 46), compared to 
85 days in those with expression > 3rd quartile (n = 16). The 
log-rank p-value is shown.
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mRNA expression greater than the 3rd quartile had a
shorter median time to treatment failure (12 vs 23 weeks).
It is assumed that higher TS and ERCC1 gene expression
translates into greater protein expression and enzymatic
activity.
The lack of importance of TS and TP gene expression in
predicting TTF may possibly be explained by the trial
design which involved dose escalation of Xel; some sub-
jects received lower Xel doses than that eventually recom-
mended. In this cohort, we observed that high DPD
mRNA levels accompanied high TP mRNA levels. It is pos-
sible that the theoretical benefit of high TP expression,
which is expected to lead to increased intracellular release
of 5-FU, is offset by increased catabolism of 5-FU.
In summary, in this trial involving predominantly pre-
treated colorectal cancer patients, higher levels of TS
mRNA expression appeared to have a predictive value in
identifying those subjects with a greater probability of
early disease progression during treatment with XelOX.
Subjects whose metastatic tumor tissue had TS mRNA
expression below the median tended to have longer
median survival by about 18 weeks. Since TS mRNA
expression did not correlate with improved TTF, low TS
expression in this study may be more of a prognostic than
a predictive factor. Information on subsequent therapies
is not available. The importance of gene expression of per-
tinent 5-FU-critical targets may be offset with combina-
tion therapy and the availability of salvage regimens. For
example, high TS tumor expression does not preclude
response to 5-FU given in combination with irinotecan
[33,34].
Finally, there has been some discordance in reports con-
cerning expression of various tumor markers in paired pri-
mary and metastatic disease. Our observation that the
expression of these four tumor markers in metastatic tis-
sue was significantly higher than the primary tumor in the
setting of a relatively long interval between obtaining the
specimens (1.8 years) highlights the importance of speci-
fying the interval between procurement of these tumor
samples in published manuscripts.
Conclusion
Gene expression of TS, DPD, ERCC1 and ERCC1 in meta-
static tissue was significantly higher than in primary
tumor. High ERCC1 mRNA levels in metastatic tumor was
associated with a shorter TTF. Lower expression of TS
mRNA correlated with a lower chance of early PD with
XelOX therapy and improved overall survival.
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